iShares Biotechnology ETF
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of -$126,670,990 last year. Net change in cash is therefore $317,591,180.
Cash Flow
| 2010 | 444.26M | 0 | -126.67M |
|---|
IBB Cash Flow Statement (2010 – 2010)
| 2010 | |
|---|---|
Cash at beginning of period | 0 |
Operating activities | |
Net income | 444.26M |
| Adjustments to reconcile net income to cash generated by operating activities: | |
Depreciation and amortization | 0 |
Stock-based compensation expense | 0 |
| Deferred income tax benefit | 0 |
| Changes in operating assets and liabilities: | |
Accounts receivable, net | 0 |
Inventories | 0 |
Accounts payable | 0 |
Cash generated by operating activities | 444.26M |
Investing activities | |
Purchases Of Investments | 0 |
Investments In Property Plant And Equipment | 0 |
Acquisitions Net | 0 |
Cash generated by investing activities | 0 |
Financing activities | |
Common Stock Issued | 0 |
Payments for dividends | 0 |
Repurchases of common stock | -126.67M |
Repayments of term debt | 0 |
Cash used in financing activities | -126.67M |
Net Change In Cash | 317.59M |
Cash at end of period | 317.59M |